Efficacy of Epidural Analgesia in Patients with Cancer Pain: A Retrospective Observational Study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Pain in terminal cancer patients may be refractory to systemic analgesics or associated with adverse drug reactions to analgesics. Epidural analgesia has been effectively used in such patients for pain control. However, this method does not provide pain relief to all patients. The efficacy and complications of continuous epidural analgesia were evaluated for expanding efficacy in terminal cancer patients. Materials and Methods: The charts of patients who received epidural analgesia for over 5 years for the control of terminal cancer pain were reviewed retrospectively. Results: Ninety-six patients received 127 epidural catheters. The mean duration for epidural catheterization was 31.5±55.6 (5-509) days. The dose of epidural morphine increased by 3.5% per day. The efficacy of epidural analgesia at 2 weeks follow up revealed improved pain control (n=56), as the morphine equivalent drug dose dropped from 213.4 mg/day to 94.1 mg/day (p<0.05) at 2 weeks follow up. Accordingly, after 2 weeks institution of epidural analgesia, there was a significant reduction in the proportion of patients with severe pain, from 78.1% to 19.6% (p<0.05). Conclusion: Epidural analgesia was an effective pain control method in patients with terminal cancer pain, however, a systematized algorithm for the control of cancer-related pain in needed.
Abstract
Purpose: Pain in terminal cancer patients may be refractory to systemic analgesics or associated with adverse drug reactions to analgesics. Epidural analgesia has been effectively used in such patients for pain control. However, this method does not provide pain relief to all patients. The efficacy and complications of continuous epidural analgesia were evaluated for expanding efficacy in terminal cancer patients. Materials and Methods: The charts of patients who received epidural analgesia for over 5 years for the control of terminal cancer pain were reviewed retrospectively. Results: Ninety-six patients received 127 epidural catheters. The mean duration for epidural catheterization was 31.5±55.6 (5-509) days. The dose of epidural morphine increased by 3.5% per day. The efficacy of epidural analgesia at 2 weeks follow up revealed improved pain control (n=56), as the morphine equivalent drug dose dropped from 213.4 mg/day to 94.1 mg/day (p<0.05) at 2 weeks follow up. Accordingly, after 2 weeks institution of epidural analgesia, there was a significant reduction in the proportion of patients with severe pain, from 78.1% to 19.6% (p<0.05). Conclusion: Epidural analgesia was an effective pain control method in patients with terminal cancer pain, however, a systematized algorithm for the control of cancer-related pain in needed.
참고문헌 (23)
- Ministry of Health and Welfare, "Department of Central Cancer Registry, 2006-2007 cancer statistics", 1~34 (2009)
- Goudas LC, "The epidemiology of cancer pain", Cancer Invest, 23, pp.182~190 (2005)
- Meuser T, "Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology", Pain, 93, pp.247~257 (2001)
- Benedetti C, "NCCN Practice Guidelines for Cancer Pain", Oncology, 14, pp.135~150 (2000)
- Zech DF, "Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study", Pain, 63, pp.65~76 (1995)
- Samuelsson H, "Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience", J Pain Symptom Manage, 10, pp.105~112 (1995)
- Smitt PS, "Outcome and complications of epidural analgesia in patients with chronic cancer pain", Cancer, 83, pp.2015~2022 (1998)
- Samuelsson H, "Pain characterization in cancer patients and the analgetic response to epidural morphine", Pain, 46, pp.3~8 (1991)
- Du Pen SL, "Chronic epidural bupivacaine-opioid infusion in intractable cancer pain", Pain, 49, pp.293~300 (1992)
- Ballantyne JC, "Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer", Cochrane Database Syst Rev, pp.CD005178~ (2005)
- Bedder MD, "Cost analysis of two implantable narcotic delivery systems", J Pain Symptom Manage, 6, pp.368~373 (1991)
- Erdine S, "Long-term results of peridural morphine in 225 patients", Pain, 45, pp.155~159 (1991)
- Burton AW, "Epidural and intrathecal analgesia is effective in treating refractory cancer pain", Pain Med, 5, pp.239~247 (2004)
- Mercadante S., "Controversies over spinal treatment in advanced cancer patients", Support Care Cancer, 6, pp.495~502 (1998)
- Jeon YS, "Clinicians’ practice and attitudes toward cancer pain management in Korea", Support Care Cancer, 15, pp.463~469 (2007)
- Hong SH, "Change in cancer pain management in Korea between 2001 and 2006: results of two nationwide surveys", J Pain Symptom Manage, 41, pp.93~103 (2011)
- Sjöberg M, "Neuropathologic findings after long-term intrathecal infusion of morphine and bupivacaine for pain treatment in cancer patients", Anesthesiology, 76, pp.173~186 (1992)
- Congedo E, "New drugs for epidural analgesia", Curr Drug Targets, 10, pp.696~706 (2009)
- Ruppen W, "Infection rates associated with epidural indwelling catheters for seven days or longer: systematic review and meta-analysis", BMC Palliat Care, 6, pp.3~ (2007)
- Hogan Q, "Epidural opiates and local anesthetics for the management of cancer pain", Pain, 46, pp.271~279 (1991)
- Hogan QH, "Loculated? Encapsulated? Indented?", Pain, 53, pp.241~242 (1993)
- Chamberlain BH, "Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness", J Pain Symptom Manage, 38, pp.683~690 (2009)
- Mercadante S, "The inappropriate use of the epidural route in cancer pain", J Pain Symptom Manage, 13, pp.233~237 (1997)